<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328392</url>
  </required_header>
  <id_info>
    <org_study_id>Takeda IISR</org_study_id>
    <nct_id>NCT01328392</nct_id>
  </id_info>
  <brief_title>Evaluating Treatment Response in Laryngo-Pharyngeal Reflux</brief_title>
  <official_title>Evaluating Treatment Response in Laryngo-Pharyngeal Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Restech, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      Although laryno-pharyngeal reflux (LPR) and gastroesophageal reflux disease (GERD) differ in
      symptoms and treatment, they are diagnosed by the same standard 24-hour pH monitoring system
      which measures liquid reflux in the esophagus. The investigators are evaluating a new
      24-hour pharyngeal pH monitoring system by Restech which can measure acid exposure in the
      airway and can be used specifically for LPR diagnosis. The purpose of this study is to
      determine whether the Restech device is more effective than standard pH monitoring in
      predicting the response to proton pump inhibitor (PPI) acid suppression therapy using
      Dexlansoprazole in patients with symptoms and/or manifestations of LPR.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of Restech to predict LPR symptom improvement after treatment with Dexlansoprazole.</measure>
    <time_frame>3 months</time_frame>
    <description>Successful LPR symptom improvement will be defined as a 25% improvement in Reflux Symptom Index (RSI)after 3 months of Dexlansoprazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between standard pH data and Restech data (normal vs.abnormal acid exposure, using established normative data values) before and after treatment with Dexlansoprazole.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Restech acid exposure events and standard pH monitoring acid exposure events.</measure>
    <time_frame>3 months</time_frame>
    <description>Using a method similar to the calculation of a symptom index for each study in each patient, to determine the percentage of time in which a Restech-detected acid event occurs at the same time as an acid event detected on standard pH monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laryngoscopic findings pre and post Dexlansoprazole treatment.</measure>
    <time_frame>3 months</time_frame>
    <description>Expressed as Reflux Finding Score (RFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between RSI and general GERD symptom questionnaire scores on and off Dexlansoprazole.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RSI and general GERD symptom questionnaire scores with Restecha dn standard pH values.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole</intervention_name>
    <description>30mg a day, 3 months</description>
    <other_name>Dexilant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old or above

          -  Have a clinical diagnosis of LPR

          -  Able and willing to provide consent

        Exclusion Criteria:

          -  History of any previous anti-reflux operation or procedure

          -  History of pharyngeal or laryngeal surgery

          -  History of larngeal or hypolaryngeal neoplasm

          -  Allergy or significant adverse reaction to PPI

          -  Patient on PPI therapy within 4 weeks prior to enrollment

          -  A cumulative history of PPI therapy equal to or greater than 3 months

          -  History of noncompliance with medication or study protocols

          -  Enrolled in another clinical trial using investigational medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brant K Oelschlager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brant K Oelschalger, MD</last_name>
    <phone>206-543-3518</phone>
    <email>brant@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brant K Oelschlager, MD</last_name>
      <phone>206-543-3518</phone>
      <email>brant@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Brant K Oelschlager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 31, 2011</lastchanged_date>
  <firstreceived_date>March 30, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Brant Oelschlager, MD</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>LPR</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
